New First-Line Treatment Approved for NSCLC with an EGFR Mutation

2018-09-28T14:51:23+00:00September 28th, 2018|Hot Topics, News|

Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based on a randomized trial that showed a significant improvement in progression-free survival for patients who received VIZIMPRO compared to the standard-of-care treatment. VIZIMPRO, an EGFR inhibitor targeted therapy, is an oral drug that is taken once a day. The following treatments [...]

No announcement available or all announcement expired.